The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the
pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan
in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease in
stages CKD1, CKD2 or CKD3.